Physician profile
Suzanne F Mackey
NPI 1972574523
$97,575.00
in general payments reported to CMS, 2019-2025
11 companies · $23K in 2025
The $23K reported for 2025 was more than what 92% of Obesity Medicine (Preventive Medicine) providers received nationally (typical 2025 total: $203).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $332 · 2021: $360 · 2022: $35K · 2023: $13K · 2024: $26K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Travel and Lodging: $6,330 · Consulting Fee: $5,273 · Food and Beverage: $2,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,760.63 |
| Travel and Lodging | $6,329.62 |
| Consulting Fee | $5,272.50 |
| Food and Beverage | $2,628.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $96,405.91 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Currax Pharmaceuticals LLC | $393.36 | 2019-2025 | Contrave, Nexlizet, Nexletol |
| Lilly USA, LLC | $248.18 | 2022-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $243.08 | 2022-2025 | Freestyle Libre 3 |
| Rhythm Pharmaceuticals, INC. | $93.42 | 2023-2024 | Imcivree, Imcivree |
| Intra-Sana Laboratories | $85.20 | 2022-2023 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Endo Pharmaceuticals INC. | $37.93 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $24.47 | 2019 | |
| Vivus LLC | $17.72 | 2022 | |
| Bausch Health US, LLC | $14.82 | 2021 | |
| Eisai INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.